Daiichi Sankyo, Merck and lung cancer
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their disease progressing in a late-stage study.
Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint
Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study. Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine kinase inhibitor treatment met its primary endpoint of progression-free survival.
Merck, Daiichi post late-stage trial win for novel lung cancer therapy
Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSNKY) announced Tuesday that their jointly developed lung cancer drug patritumab deruxtecan, which belongs to a new class of targeted cancer drugs called antibody-drug conjugates (ADC),
Daiichi Sankyo-Merck's cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in some patients with a type of lung cancer. The drug helped patients live significantly longer without their cancer progressing,
FDA expands approval of breast cancer drug Kisqali
Notable Labs Pauses Implementation of Cancer Drug Volasertib Study, Announces Layoffs
Notable Labs said it is pausing implementation of the planned Phase 2 study of cancer drug Volasertib in relapsed/refractory acute myeloid leukemia. The biotechnology company also said Thursday it ...
AARP2d
Rx Drug Law Saves Some Cancer Patients More Than $7,000 in 2024
A recent survey from AARP found that roughly 40 percent of adults age 65-plus who are eligible for Medicare have either ...
Sierra Sun Times19h
NIH Reports Bone Marrow Cancer Drug Shows Success in Treatment of Rare Blood Disorder
A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient ...
Medscape1d
Case Dismissed: No Cancer Drug Delivery to Patients' Homes
Last year, the Community Oncology Alliance sued to reverse a policy that prohibits oncology practices from mailing cancer ...
Medical Xpress on MSN2d
New research could lead to better treatment for oral cancer
Dr. Chakraborty says the research opens new possibilities for oral cancer treatment, particularly addressing drug ...
Pfizer: Potential cachexia cancer drug shows life-saving promise
A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...
FierceBiotech3d
Kairos goes public with $6M IPO to fund trials of lead cancer drug
With a trio of biotechs hitting the Nasdaq on Friday, it was easy to miss a smaller-scale public debut from another ...
Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results
The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for ...